PDS Biotechnology Corp (PDSB) is a clinical-stage biopharmaceutical company whose primary mission is to transform the lives of patients by developing innovative and effective immuno-oncology treatments. The company is based in Princeton, New Jersey, and operates on a global scale.
Founded in 2005, PDSB specializes in the development of Versamune®, a proprietary clinical-stage immunotherapy platform designed to stimulate the body's immune system to target and destroy disease. From cancers to infectious diseases, this technology has the potential to revolutionize treatments for a wide array of conditions — a groundbreaking achievement in the field of medical science.
PDSB's Versamune® platform is a true testament to innovation as it uses a unique mechanism of action to activate the immune system. This is crucial in fighting cancers and diseases that hide from the body's natural defenses. The platform has shown promise in its ability to generate a specific and powerful T-cell response, while potentially reducing the adverse side effects associated with many current treatments.
As of 2021, the leading product candidate from this platform is PDS0101, an immunotherapy treatment for HPV-associated cancers. This therapy is currently undergoing Phase 2 clinical trials, underlining the company's dedication and progress in the search for more effective cancer treatments.
The company's stock trades on the NASDAQ under the ticker symbol "PDSB". PDSB has managed to secure a significant amount of funding and support from investors, which is testament to its promising future. Although it is still a relatively small company with around 11-50 employees, the progress and potential of PDSB cannot be underestimated, and it's expected to play a significant role in the field of immuno-oncology in the future.
PDS Biotechnology has not only proved to be a pioneer in the field of immuno-oncology, but also a beacon of hope for those living with illnesses that have yet remained untreatable. Its continued dedication to innovation and the development of impactful immunotherapies signifies its commitment to positively influence the lives of patients worldwide.
Innovative in its approach and relentless in its pursuit of better treatments, PDSB is more than just a biotech company -- it's a company that holds promise for the future of disease treatment.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
John Andrew Dawson has been appointed as a director to the PDS Biotechnology Corp board, effective October 18, 2026. Upon his appointment, Dawson filed an initial beneficial ownership statement with the SEC, confirming that he holds no securities, either derivative or non-derivative, in the company. PDS Biotechnology Corp (NASDAQ: PDSB) is a clinical-stage biopharmaceutical company focused on oncology and immunology.
PDS Biotechnology Corporation has appointed John Dawson CBE, Deborah Ramsdell, and Bruce Wendel to its Board of Directors, effective October 18, 2026. These appointments follow the resignations of four previous board members. The new directors bring extensive experience in corporate development, commercialization, and regulatory affairs, which PDS Biotech expects will support its advancement of PDS0301 toward a Phase 3 trial and its partnership strategy for PDS0101.